Hematopoietic Stem Cell Generation via Trpv4 Agonists and Mechanical Stretching

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The therapeutic use of hematopoietic stem cell transplantation is limited by the difficulty in finding suitable HLA-matched donors, particularly in ethnic minorities, and by complications such as graft-versus-host disease.

Innovation Solution

Methods for preparing clinical-grade hematopoietic stem cells (HSCs) by stimulating endothelial-to-HSC transition using Trpv4 agonists or cyclic 2-dimensional stretching of hemogenic endothelial cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If allogeneic HSC transplantation is performed, then patients can receive HSC treatment, but immunologic complications such as graft-versus-host disease and donor rejection occur

Engineering Contradiction:

Improvetransplantation successVSAvoidimmunologic complications

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent creates autologous HSCs by reprogramming the patient's own somatic cells (such as skin fibroblasts or blood cells) into induced pluripotent stem cells, then differentiating them into HSCs. This copying approach using the patient's own cellular material eliminates immunologic rejection and graft-versus-host disease while providing functional HSCs for transplantation

Inventive Principle:

Principle #26Copying

2Object-affected harmful factors

If autologous HSC transplantation is performed, then immunologic complications are eliminated, but the difficulty of finding suitable donors remains for certain patient populations

Engineering Contradiction:

Improveimmunologic complicationsVSAvoiddonor availability time

Core Design Contradiction:

Object-affected harmful factorsVSLoss of time

Solution Approach 1:

The patent enables patients to serve themselves as their own donors by generating autologous HSCs from their own somatic cells. This self-service approach eliminates the need to search for HLA-matched donors in registries, immediately resolving the time loss associated with donor availability while also eliminating immunologic complications

Inventive Principle:

Principle #25Self-service

3Productivity

If HSCs are generated from hemogenic endothelial cells using Trpv4 agonists or cyclic stretching, then functional HSCs can be produced, but the complexity of the differentiation process increases

Engineering Contradiction:

ImproveHSC generationVSAvoiddifferentiation process

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent employs specific parameter changes including chemical agonists (such as Yoda1 for Trpv4 channels) and physical parameters (cyclic mechanical stretching at defined frequencies and amplitudes) to trigger endothelial-to-HSC transition. These controlled parameter changes provide a standardized method to initiate differentiation while managing process complexity through defined protocols

Inventive Principle:

Principle #35Parameter changes

4Reliability

If HLA-matched allogeneic donors are sought, then immunologic compatibility can be achieved, but the time required to find a suitable donor increases

Engineering Contradiction:

Improveimmunologic compatibilityVSAvoiddonor search time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent creates autologous HSCs by reprogramming the patient's own somatic cells, eliminating the need for HLA-matched donor searches. This copying approach using the patient's own cellular material immediately resolves both the time loss associated with donor searching and ensures perfect immunologic compatibility

Inventive Principle:

Principle #26Copying

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These methods enable the generation of functional HSCs that can be used for transplantation, overcoming donor availability issues and reducing the risk of graft-versus-host disease.

Implementation Method 1

contacting the HE cells with an amount of an agonist of transient receptor potential cation channel-subfamily vanilloid member 4 (Trpv4)

Methodology Applied

Scientific EffectTrpv4 agonist activation:

Implementation Method 2

subjecting the cells to cyclic 2-dimensional stretching

Methodology Applied

Scientific EffectMechanical stretching: Mechanical Force

Data Source

PatentUS20250171740A1Methods for generating functional hematopoietic stem cells

Publication Date: 2025.05.29 CHILDRENS MEDICAL CENT CORP

AI summary

Described in the present application are methods for preparing populations of hematopoietic stem cells (HSCs), e.g., autologous and/or allogenic HSCs, using mechanical stretching or Trpv4 agonists, and methods of use of the HSCs in transplantation. In some embodiments, the methods include providing a population comprising hemogenic endothelial (HE) cells, and (i) contacting the HE cells with an amount of an agonist of transient receptor potential cation channel-subfamily vanilloid member 4 (Trpv4); and/or (ii) subjecting the cells to cyclic 2-dimensional stretching, for a time and under conditions sufficient to stimulating endothelial-to-HSC transition. Also provided herein are methods for treating subjects who have, bone marrow, metabolic, and immune diseases; the methods include administering to the subject a therapeutically effective amount of hematopoietic stem cells (HSCs) obtained by a method described herein.